Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Hemophagocytosis by blasts in acute lymphoblastic leukemia.

Klein E, Derrieux C, Dulucq S.

Blood Res. 2019 Mar;54(1):2. doi: 10.5045/br.2019.54.1.2. Epub 2019 Mar 21. No abstract available.

2.

Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.

Dulucq S, Etienne G, Morisset S, Klein E, Chollet C, Robbesyn F, Turcq B, Tigaud I, Hayette S, Nicolini FE, Mahon FX.

Ann Hematol. 2019 May;98(5):1159-1168. doi: 10.1007/s00277-019-03633-x. Epub 2019 Feb 23.

PMID:
30798348
3.

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.

Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noël-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Véronèse L, Réa D, Gervais C, Theisen O, Terré C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C; Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC).

Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20.

4.

Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib.

Nicolini FE, Alcazer V, Cony-Makhoul P, Heiblig M, Morisset S, Fossard G, Bidet A, Schmitt A, Sobh M, Hayette S, Mahon FX, Dulucq S, Etienne G.

Exp Hematol. 2018 Aug;64:97-105.e4. doi: 10.1016/j.exphem.2018.05.003. Epub 2018 May 23.

PMID:
29800673
5.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX; French Chronic Myeloid Leukemia Study Group.

Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3.

PMID:
29723417
6.

Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.

Bidet A, Chollet C, Gardembas M, Nicolini FE, Genet P, Delmer A, Caillot D, Dulucq S, Mahon FX, Lippert E.

Br J Haematol. 2018 Jul;182(1):148-152. doi: 10.1111/bjh.14748. Epub 2017 May 9. No abstract available.

PMID:
28485070
7.

Deep molecular responses for treatment-free remission in chronic myeloid leukemia.

Dulucq S, Mahon FX.

Cancer Med. 2016 Sep;5(9):2398-411. doi: 10.1002/cam4.801. Epub 2016 Jul 1. Review.

8.

A case of acute promyelocytic leukaemia with unusual cytological features and a ZBTB16-RARA fusion gene.

Lechevalier N, Dulucq S, Bidet A.

Br J Haematol. 2016 Aug;174(4):502. doi: 10.1111/bjh.14198. Epub 2016 Jun 15. No abstract available.

PMID:
27302179
9.

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.

Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S.

Leukemia. 2016 Sep;30(9):1844-52. doi: 10.1038/leu.2016.90. Epub 2016 Apr 25.

10.

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.

Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Amé S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX.

Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7.

PMID:
26687426
11.

Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts.

Huet S, Dulucq S, Chauveau A, Ménard A, Chomel JC, Maisonneuve H, Legros L, Perrin MC, Ferrant E, Moreilhon C, Couturier MA, Sujobert P, Magaud JP, Ugo V, Chabane K, Raynaud S, Hayette S; GBMHM (Groupe des Biologistes Moléculaires des Hémopathies Malignes, French Molecular Biology Group in Hematology).

Genes Chromosomes Cancer. 2015 Oct;54(10):595-605. doi: 10.1002/gcc.22263. Epub 2015 Aug 7.

PMID:
26252834
12.

A novel method for room temperature distribution and conservation of RNA and DNA reference materials for guaranteeing performance of molecular diagnostics in onco-hematology: A GBMHM study.

Cayuela JM, Mauté C, Fabre AL, Nibourel O, Dulucq S, Delabesse E, Villarèse P, Hayette S, Mozziconacci MJ, Macintyre E; GBMHM.

Clin Biochem. 2015 Oct;48(15):982-7. doi: 10.1016/j.clinbiochem.2015.04.004. Epub 2015 Apr 12.

PMID:
25872147
13.

[Pitfalls in hemoglobin oxygen saturation measurement: a case of chronic desaturation].

Eguienta S, Martigne L, Dulucq S, Fayon M.

Arch Pediatr. 2015 Apr;22(4):390-2. doi: 10.1016/j.arcped.2015.01.009. Epub 2015 Feb 26. French.

PMID:
25727475
14.

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC, Hochhaus A.

Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. Epub 2015 Feb 5. Review.

15.

Transient abnormal myelopoiesis (TAM) in a neonate without Down syndrome.

Bidet A, Dulucq S, Aladjidi N.

Br J Haematol. 2015 Jan;168(1):2. doi: 10.1111/bjh.13166. Epub 2014 Oct 13. No abstract available.

PMID:
25308890
16.

ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?

Etienne G, Dulucq S, Lascaux A, Schmitt A, Bidet A, Fort MP, Lippert E, Bureau C, Adiko D, Hayette S, Reiffers J, Nicolini FE, Mahon FX.

Am J Hematol. 2015 Jan;90(1):37-41. doi: 10.1002/ajh.23864. Epub 2014 Oct 25.

17.

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR.

White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikienė E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, Martinelli G, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedéu J, Nymoen DA, Leibundgut EO, Ozbek U, Pajič T, Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VH, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, Müller MC, Hochhaus A, Schimmel H, Cross NC, Emons H.

Leukemia. 2015 Feb;29(2):369-76. doi: 10.1038/leu.2014.217. Epub 2014 Jul 18.

18.

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.

Dulucq S, Laverdière C, Sinnett D, Krajinovic M.

Expert Opin Drug Metab Toxicol. 2014 May;10(5):699-719. doi: 10.1517/17425255.2014.893294. Epub 2014 Mar 27. Review.

PMID:
24673379
19.

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.

Etienne G, Dulucq S, Nicolini FE, Morisset S, Fort MP, Schmitt A, Etienne M, Hayette S, Lippert E, Bureau C, Tigaud I, Adiko D, Marit G, Reiffers J, Mahon FX.

Haematologica. 2014 Mar;99(3):458-64. doi: 10.3324/haematol.2013.095158. Epub 2013 Dec 20.

20.

Performance of rapid diagnostic tests for imported malaria in clinical practice: results of a national multicenter study.

Houzé S, Boutron I, Marmorat A, Dalichampt M, Choquet C, Poilane I, Godineau N, Le Guern AS, Thellier M, Broutier H, Fenneteau O, Millet P, Dulucq S, Hubert V, Houzé P, Tubach F, Le Bras J, Matheron S.

PLoS One. 2013 Sep 30;8(9):e75486. doi: 10.1371/journal.pone.0075486. eCollection 2013.

21.

From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome.

Bouchet S, Dulucq S, Pasquet JM, Lagarde V, Molimard M, Mahon FX.

Leukemia. 2013 Aug;27(8):1757-9. doi: 10.1038/leu.2013.13. Epub 2013 Jan 16. No abstract available.

PMID:
23392357
22.

Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.

Labouré G, Dulucq S, Labopin M, Tabrizi R, Guérin E, Pigneux A, Lafarge X, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Lascaux A, Marit G, Mahon FX, Boiron JM, Milpied N, Vigouroux S.

Biol Blood Marrow Transplant. 2012 Dec;18(12):1845-50. doi: 10.1016/j.bbmt.2012.06.012. Epub 2012 Jul 2.

23.

Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells.

Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche S, Mahon FX, Pasquet JM.

Blood. 2011 Aug 25;118(8):2211-21. doi: 10.1182/blood-2010-10-313692. Epub 2011 Jul 5.

24.

Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience.

de Guibert S, Peffault de Latour R, Varoqueaux N, Labussière H, Rio B, Jaulmes D, Eveillard JR, Dulucq S, Stoppa AM, Bouscary D, Girodon F, Bonnotte B, Laskri D, Socié G, Lamy T.

Haematologica. 2011 Sep;96(9):1276-83. doi: 10.3324/haematol.2010.037531. Epub 2011 May 23.

25.

The pharmacogenetics of imanitib.

Dulucq S, Krajinovic M.

Genome Med. 2010 Nov 30;2(11):85. doi: 10.1186/gm206.

26.

Alignments of RNA structures.

Blin G, Denise A, Dulucq S, Herrbach C, Touzet H.

IEEE/ACM Trans Comput Biol Bioinform. 2010 Apr-Jun;7(2):309-22. doi: 10.1109/TCBB.2008.28.

27.

DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia.

Al-Shakfa F, Dulucq S, Brukner I, Milacic I, Ansari M, Beaulieu P, Moghrabi A, Laverdière C, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Krajinovic M.

Clin Cancer Res. 2009 Nov 15;15(22):6931-8. doi: 10.1158/1078-0432.CCR-09-0641. Epub 2009 Oct 27.

28.

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, Molimard M, Krajinovic M, Mahon FX.

Blood. 2008 Sep 1;112(5):2024-7. doi: 10.1182/blood-2008-03-147744. Epub 2008 Jun 4.

29.

DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL.

Dulucq S, St-Onge G, Gagné V, Ansari M, Sinnett D, Labuda D, Moghrabi A, Krajinovic M.

Blood. 2008 Apr 1;111(7):3692-700. Epub 2007 Dec 20.

30.

Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis.

Krajinovic M, Costea I, Primeau M, Dulucq S, Moghrabi A.

Pharmacogenomics J. 2005;5(6):374-80.

PMID:
16130010

Supplemental Content

Loading ...
Support Center